



Figure S2. Median time to discontinuation: sensitivity analyses of treatment-naïve men (no prior combination therapy)* (a); index combination first prescribed on the same date* (b); and men who received an α -blocker plus an antimuscarinic as combination therapy within 60 days† (c).

*Men who received α -blocker plus antimuscarinic; †Men who initiated α -blocker and antimuscarinic combination therapy within a 60 day window. 5-ARI: 5 α -reductase inhibitor; CI: confidence intervals; FDC: fixed-dose combination; HR: hazard ratio; TTD: time to discontinuation